Related Experiment Video
Updated: Aug 9, 2026
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
Published on: June 22, 2016
Characterization of human blood dendritic cell subsets
Kelli P A MacDonald1, David J Munster, Georgina J Clark
1Dendritic Cell Laboratory, Mater Medical Research Institute, Mater Misericordiae Hospitals, South Brisbane, Australia.
Insights
This study characterizes dendritic cell (DC) heterogeneity in clinical preparations. Researchers identified five distinct DC subsets with varying immune functions, paving the way for standardized DC therapies.
Area of Science:
- Immunology
- Cell Biology
Background:
- Dendritic cells (DCs) are crucial for initiating immune responses and are being explored for clinical applications.
- Standardized DC preparations are vital for reliable therapeutic outcomes.
- Existing DC preparations exhibit significant cellular heterogeneity, impacting their function.
Purpose of the Study:
- To define the cellular composition of peripheral blood mononuclear cell (PBMC)-derived lineage-negative (Lin(-)) HLA-DR(+) DC preparations.
- To characterize the distinct phenotypes and functional capacities of identified DC subsets.
- To provide a basis for standardizing DC populations in future research and therapeutic studies.
Main Methods:
- Utilized flow cytometry and a comprehensive panel of monoclonal antibodies (mAbs) to analyze PBMC-derived Lin(-) HLA-DR(+) cells.
- Prepared Lin(-) cells by depleting PBMCs with specific mAbs against CD3, CD14, CD19, CD11b, and either CD16 or CD56.
- Identified and quantified five distinct DC subsets (CD123, CD1b/c, CD16, BDCA-3, CD34) within the Lin(-) HLA-DR(+) population.
Main Results:
- The Lin(-) HLA-DR(+) population was resolved into five non-overlapping subsets with distinct phenotypes and differential expression of various cell surface markers.
- The study confirmed poor in vitro viability for CD123(+) DCs and also identified poor survival in the CD16(+) CD11c(+) DC subset.
- Allostimulatory capacity varied significantly among subsets, ranked as CD1b/c > CD16 > BDCA-3 > CD123 > CD34 in allogeneic mixed leukocyte reactions.
Conclusions:
- Standardized peripheral blood-derived dendritic cell preparations contain significant cellular heterogeneity.
- Distinct dendritic cell subsets possess unique phenotypic profiles and functional capabilities, including varying allostimulatory potential.
- Characterization of these subsets is essential for optimizing dendritic cell selection for molecular, functional, and therapeutic applications.
Abstract:
Dendritic cells (DCs) are key antigen-presenting cells for stimulating immune responses and they are now being investigated in clinical settings. Although defined as lineage-negative (Lin(-)) HLA-DR(+) cells, significant heterogeneity in these preparations is apparent, particularly in regard to the inclusion or exclusion of CD14(+), CD16(+), and CD2(+) cells. This study used flow cytometry and a panel of monoclonal antibodies (mAbs), including reagents from the 7th Leukocyte Differentiation Antigen Workshop, to define the cellular composition of 2 standardized peripheral blood mononuclear cell (PBMCs)-derived Lin(-) HLA-DR(+) preparations. Lin(-) cells were prepared from PBMCs by depletion with CD3, CD14, CD19, CD11b, and either CD16 or CD56 mAbs. Analysis of the CD16-replete preparations divided the Lin(-) HLA-DR(+) population into 5 nonoverlapping subsets (mean +/- 1 SD): CD123 (mean = 18.3% +/- 9.7%), CD1b/c (18.6% +/- 7.6%), CD16 (49.6% +/- 8.5%), BDCA-3 (2.7% +/- 1.4%), and CD34 (5.0% +/- 2.4%). The 5 subsets had distinct phenotypes when compared with each other, monocytes, and monocyte-derived DCs (MoDCs). The CD85 family, C-type lectins, costimulatory molecules, and differentiation/activation molecules were also expressed differentially on the 5 Lin(-) HLA-DR(+) subsets, monocytes, and MoDCs. The poor viability of CD123(+) DCs in vitro was confirmed, but the CD16(+) CD11c(+) DC subset also survived poorly. Finally, the individual subsets used as stimulators in allogeneic mixed leukocyte reactions were ranked by their allostimulatory capacity as CD1b/c > CD16 > BDCA-3 > CD123 > CD34. These data provide an opportunity to standardize the DC populations used for future molecular, functional and possibly even therapeutic studies.
